A glossary of key terms related to neurodegeneration, neuro-longevity and adjacent fields. Perfect for flashcard revision, bookmarking to return to when you need help understanding a specific term or perhaps a bit of light reading? Maybe not the last one.
A
• Acetylcholine (ACh): A neurotransmitter essential for muscle control and brain function, especially in learning, memory, and attention. Many neurons that use acetylcholine degenerate in Alzheimer’s disease, leading to lower ACh levels and memory problems. Treatments for dementia often try to boost acetylcholine to improve cognitive symptoms.
• Ageing (Brain ageing): The natural process of gradual decline in brain structure and function over time. With ageing, the brain slowly shrinks (losing about 5% of its volume per decade after age 40), and important neurotransmitters like dopamine diminish (around 10% loss per decade). These changes can lead to slower thinking and mild forgetfulness, and ageing is the most significant risk factor for neurodegenerative diseases.
• Alpha-synuclein: A protein abundant in brain neurons (especially at synapses) that helps regulate neurotransmitter release. In Parkinson’s disease and related disorders (called synucleinopathies), alpha-synuclein misfolds and clumps together into insoluble fibrils; these aggregates form Lewy bodies, hallmark protein deposits that disrupt cell function and lead to neuron death.
• Alzheimer’s disease (AD): The most common neurodegenerative disease and leading cause of dementia. It causes progressive memory loss and cognitive decline, as neurons in the brain die over time. A hallmark of AD is the accumulation of two abnormal protein structures – amyloid-beta plaques and tau neurofibrillary tangles – which disrupt brain cell communication and ultimately kill neurons. (See Amyloid plaques and Neurofibrillary tangles.)
• Amyloid plaques: Clumps of a protein fragment called beta-amyloid that accumulate in the spaces between nerve cells in the brain. These sticky plaques disrupt cell-to-cell communication and trigger inflammation, and their buildup is a cardinal feature of Alzheimer’s pathology. Over time, widespread amyloid plaque deposition is associated with synapse loss and neuron death in AD.
• Amyloid-beta (Aβ): A short peptide (protein fragment) that is the main ingredient of amyloid plaques in Alzheimer’s disease. Amyloid-beta is produced when a larger protein (amyloid precursor protein, APP) is cut by specific enzymes. Certain forms of Aβ (especially Aβ₄₂) are prone to misfold and stick together, forming toxic aggregates that harm neurons.
• Amyotrophic lateral sclerosis (ALS): Also known as Lou Gehrig’s disease, a progressive neurodegenerative disorder that selectively attacks motor neurons in the brain and spinal cord. As these neurons disintegrate, patients lose the ability to control voluntary muscles, leading to muscle weakness, paralysis, and ultimately difficulty breathing. ALS usually progresses rapidly and is fatal within a few years of onset.
• Antisense oligonucleotide (ASO): A short, single-stranded piece of DNA or RNA designed to bind to a specific messenger RNA (mRNA) molecule. By pairing with its target mRNA, an ASO can block production of a harmful protein or alter the RNA’s processing, effectively “silencing” or modifying genes involved in disease. ASO therapies are being tested for neurodegenerative diseases like ALS and Huntington’s (to reduce toxic proteins).
• Apoptosis: A form of programmed cell death in which cells activate an internal “suicide” program to self-destruct in an orderly way. This process is a normal part of development and tissue maintenance, but in neurodegenerative diseases, excessive apoptosis can lead to loss of neurons beyond what is normal, contributing to brain damage.
• Apolipoprotein E (ApoE): A protein that helps transport cholesterol and other lipids in the bloodstream and brain. It comes in three common genetic forms (E2, E3, E4); the APOE ε4 variant is the strongest genetic risk factor for late-onset Alzheimer’s disease. ApoE influences how the brain clears amyloid-beta and repairs neurons, which is why certain forms (especially ApoE4) increase the risk of neurodegeneration.
• Artificial intelligence (AI) in neuroscience: The use of advanced algorithms and machine learning to help understand the brain and neurological diseases. AI systems can analyse brain scans and biological data far faster than humans – for example, some models can detect Alzheimer’s disease in MRI images with over 90% accuracy. Researchers also use AI to discover patterns in genetic and protein data, which can reveal new drug targets or biomarkers for neurodegenerative disorders.
• Astrocyte: A star-shaped glial cell in the central nervous system that supports and nourishes neurons. Astrocytes help regulate the formation and pruning of synapses and contribute to the blood-brain barrier that protects the brain. In injury or disease, astrocytes become reactive and can either aid in repair or, if overactive, contribute to scar formation and inflammation.
• Autophagy: Literally “self-eating,” a cellular recycling process in which cells break down and dispose of their own damaged components (such as misfolded proteins or worn-out organelles) in lysosomes. Autophagy helps keep neurons healthy by preventing toxic debris buildup; when this process falters, protein aggregates can accumulate and contribute to neurodegenerative diseases. (Enhancing autophagy is being explored as a therapy to clear proteins like amyloid or alpha-synuclein.)
• Axon: The long, fiber-like extension of a neuron that transmits electrical impulses to other neurons or target cells. Axons are often insulated with myelin to speed up signal transmission. Damage to axons (e.g. in trauma or diseases like multiple sclerosis) disrupts neural communication and can lead to loss of function.
B
• Bioinformatics: An interdisciplinary field that develops and uses computational methods to analyse large biological datasets. Bioinformatics combines biology, computer science, and statistics to manage and interpret information such as DNA sequences, protein structures, and gene expression profiles. In neuroscience, it’s crucial for crunching big data (like genomic variants linked to Alzheimer’s) and discovering patterns that human analysis alone might miss.
• Biomarker: A measurable biological indicator of a normal or disease process. In neurodegenerative diseases, biomarkers can be molecules in blood or cerebrospinal fluid (for example, tau or neurofilament light proteins) or brain imaging findings that signal the presence or progression of a condition. Doctors use biomarkers for early diagnosis, tracking disease progression, and monitoring responses to treatment.
• Blood–brain barrier (BBB): A highly selective, semipermeable barrier formed by tightly-joined cells lining the brain’s capillaries. The BBB allows essential nutrients into the brain and keeps many toxins and pathogens out. However, it also blocks many medications from entering the brain, which poses a challenge for treating neurological diseases.
• Brain age clock: A measurement that estimates the biological age of a person’s brain (which may differ from their chronological age). Often based on epigenetic clocks (patterns of DNA methylation that correlate with ageing) or on brain imaging data, a brain age clock indicates whether an individual’s brain is ageing faster or slower than average. This tool is used in research to assess brain health and to test whether interventions (like certain diets or drugs) can slow brain ageing.
• Brain–computer interface (BCI): A technology that enables direct communication between the brain’s electrical signals and an external computer or device . BCIs decode brain activity (via sensors like EEG electrodes or implanted chips) and translate it into commands – for example, allowing a person to move a prosthetic limb or control a cursor using their thoughts. This emerging technology holds promise for helping paralysed patients and for augmenting human capabilities.
• Brain-derived neurotrophic factor (BDNF): A protein growth factor that acts like fertiliser for neurons, helping them survive, grow, and form new connections . BDNF is crucial for synaptic plasticity (the brain’s ability to strengthen connections with experience) and is heavily involved in learning and memory. Lower levels of BDNF have been linked to neurodegenerative conditions and depression, while exercise and other interventions can boost BDNF levels and support brain health.
C
• Central nervous system (CNS): The part of the nervous system consisting of the brain and spinal cord. The CNS processes information and controls most functions of mind and body. (By contrast, the peripheral nervous system encompasses all nerves outside the CNS.) Many neurodegenerative diseases are CNS disorders (e.g. Alzheimer’s affects the brain; ALS affects CNS motor neurons).
• Cerebrospinal fluid (CSF): The clear, watery fluid that surrounds and cushions the brain and spinal cord. CSF circulates nutrients and removes waste products from the brain. Doctors can test CSF (via a spinal tap) for biomarkers – for example, low CSF amyloid and high CSF tau are indicative of Alzheimer’s disease, as they reflect the deposition of amyloid in the brain and neuron damage, releasing tau into CSF.
• Cognitive reserve: The brain’s resilience or ability to cope with damage by using alternate networks or strategies. Individuals with high cognitive reserve (often built through education, mental stimulation, or social engagement) can tolerate more brain pathology (plaques, tangles, small strokes, etc.) before showing clinical symptoms. In essence, it’s extra “brain bandwidth” that delays the outward signs of neurodegeneration.
• CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats): A groundbreaking gene-editing technology that allows scientists to make precise, targeted changes to DNA. CRISPR uses a specialised enzyme (like Cas9), guided by a custom RNA sequence, to cut DNA at a chosen site. This enables researchers to disable or correct genes. CRISPR is being explored in neurological disorders – for example, to remove toxic gene mutations or to edit immune cells to better clear amyloid plaques.
D
• Deep brain stimulation (DBS): A treatment that involves implanting electrodes in specific areas of the brain to deliver mild electrical pulses that modulate neural activity. Often described as a “brain pacemaker,” DBS is an established therapy for Parkinson’s disease (to reduce tremors and rigidity) and is being studied in other conditions. The electrical stimulation can normalise abnormal brain circuit activity without permanently damaging tissue.
• Dementia: An umbrella term for a decline in mental ability severe enough to interfere with daily life. Dementia typically involves memory loss plus impairment in other cognitive functions (language, problem-solving, etc.). Alzheimer’s disease is the most common cause of dementia. Other forms include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia is not a normal part of ageing – it results from underlying brain disease or damage.
• Demyelination: The loss or damage of myelin, the fatty insulation around axons that helps nerve signals travel quickly. Demyelination slows or blocks electrical impulses in nerves. It is the hallmark of multiple sclerosis (an autoimmune disorder where the immune system attacks myelin) and can also occur after infections or in neurodegenerative disorders affecting white matter. Symptoms vary but often include weakness, numbness, and impaired coordination.
• Dendrite: The branch-like extension of a neuron that receives incoming signals from other nerve cells. Dendrites are covered with tiny protrusions called spines where synapses occur. The number and structure of dendrites (and spines) affect how neurons integrate information. Loss of dendrites and spines is often seen in brain ageing and Alzheimer’s, corresponding to reduced synaptic connectivity.
• DNA methylation: A chemical modification to DNA where a methyl group is added to a cytosine nucleotide (often in a CpG context). DNA methylation is an epigenetic mechanism that can turn genes off. Patterns of DNA methylation change with age and environment. (See Epigenetics and Epigenetic clock – DNA methylation levels at specific sites are used to measure biological ageing.)
• Donepezil: A medication (brand name Aricept) that inhibits acetylcholinesterase – the enzyme that breaks down acetylcholine. By blocking this enzyme, donepezil increases acetylcholine levels in the brain. It is prescribed to treat mild to moderate Alzheimer’s disease symptoms, leading to modest improvements in memory and thinking. (It doesn’t stop the disease, but it can temporarily ease symptoms by boosting neurotransmitter signalling.)
• Dopamine: A neurotransmitter that plays key roles in movement, motivation, and reward. In the motor system, dopamine is critical for smooth, controlled movement – the death of dopamine-producing neurons in the substantia nigra causes the motor symptoms of Parkinson’s disease. Dopamine is also central to the brain’s pleasure and reward circuits, influencing mood and behaviour. Many Parkinson’s drugs and some psychiatric drugs work by increasing or modulating dopamine.
E
• Epigenetic clock: A biochemical test that estimates biological age based on epigenetic markers (typically DNA methylation patterns). Pioneered by Steve Horvath and others, epigenetic clocks compare methylation levels at certain sites on the genome to reference patterns and output an “age.” If one’s epigenetic age is higher than their actual age, it suggests accelerated ageing (and possibly higher disease risk). These clocks are used in research on ageing and rejuvenation therapies.
• Epigenetics: The study of heritable changes in gene activity that do not involve changes to the DNA sequence. Epigenetic mechanisms (like DNA methylation and histone modification) act as gene “switches” – turning genes on or off in response to development or environment. Epigenetic changes accumulate with age. In neurodegeneration, certain epigenetic patterns may influence disease onset or progression, and interventions that target epigenetics (like HDAC inhibitors) are being explored to activate protective genes or silence harmful ones.
• Excitotoxicity: Cell damage or death caused by excessive stimulation by excitatory neurotransmitters such as glutamate. When neurons are overactivated (for instance, during a stroke or severe seizure), too much glutamate allows calcium to flood into cells, triggering destructive enzymes and free radicals. Excitotoxicity is a mechanism of acute brain injury and may also contribute to chronic neuron loss in diseases by slow, chronic overstimulation of certain circuits.
• Exosome: A tiny extracellular vesicle (50–150 nanometers) that cells release to transport proteins, lipids, and RNA as a form of cell-to-cell communication. Neurons and glia secrete exosomes, which can carry biomolecules through the CSF or blood. In neurodegenerative disease, exosomes may contain pathological proteins (like tau or alpha-synuclein) and contribute to their spread, but they also offer a potential source of disease biomarkers (e.g. analysing neuron-derived exosomes from blood for early diagnostic clues).
F
• Frontotemporal dementia (FTD): A group of neurodegenerative conditions characterised by progressive degeneration of the frontal and/or temporal lobes of the brain. Unlike Alzheimer’s (which first impacts memory), FTD often presents with marked changes in personality, behaviour, or language. For example, a person with FTD may develop apathy, disinhibition (socially inappropriate behaviour), or loss of word meaning (semantic dementia). FTD typically starts at a younger age (50s or 60s) than Alzheimer’s and can be caused by abnormal proteins like tau or TDP-43 (see Tauopathy and TDP-43).
• Functional MRI (fMRI): An imaging technique that reveals brain activity by measuring changes in blood flow and blood oxygenation. When a brain region is more active, it consumes more oxygen and blood flow increases; fMRI detects these changes (the BOLD signal) to create maps of which brain areas “light up” during specific tasks or at rest. It’s widely used in research to study brain function and is sometimes used clinically (e.g. to map vital functions before brain surgery).
• Free radicals: (See Reactive oxygen species.)
G
• Gene therapy: An experimental technique for treating disease by altering a person’s genes. This could mean adding a healthy copy of a missing or defective gene, inactivating a mutant gene, or giving cells a new function. In neurodegeneration, gene therapy might deliver genes that help neurons survive (like growth factors) or use viral vectors to knock down toxic genes. For example, gene therapy trials in Parkinson’s have delivered enzymes for dopamine synthesis into the striatum to boost dopamine production.
• Genomics: The study of an organism’s entire genome (all of its DNA) – including sequencing, mapping, and analysing genes and their functions. Genomics in neurodegeneration involves searching for genetic variants that increase disease risk (through genome-wide association studies), investigating familial gene mutations (like APP, PSEN1, PSEN2 in Alzheimer’s; HTT in Huntington’s; LRRK2, SNCA in Parkinson’s), and using genomic data to understand pathways that go awry in disease.
• Glial cells (glia): The support cells of the nervous system (as opposed to neurons). Glia include astrocytes, microglia, and oligodendrocytes in the CNS, as well as Schwann cells and satellite cells in the PNS. Once thought of as mere “nerve glue,” glial cells are now known to actively participate in brain function – regulating synapses, providing nutrients, insulating axons, and immune defence. Dysfunction in glia (e.g. overactive microglia causing inflammation, or loss of oligodendrocytes causing demyelination) plays a significant role in neurodegenerative disease.
• Glymphatic system: A waste-clearance system in the brain that operates mainly during sleep. It involves convective fluid flow through spaces around blood vessels (driven by pulsations and aided by channels in astrocytes) to flush out metabolic waste from brain tissue. The glymphatic system clears toxins like amyloid-beta and tau; impaired glymphatic clearance is thought to contribute to protein accumulation in diseases like Alzheimer’s. (The term “glymphatic” reflects its dependence on glial cells and its functional analogy to the lymphatic system.)
• Genome-wide association study (GWAS): An approach in genetics where researchers rapidly scan the genomes of many individuals to find genetic variants associated with a particular disease or trait. In a GWAS for Alzheimer’s, for example, scientists compare DNA from thousands of people with AD to controls, looking for single-nucleotide polymorphisms (SNPs) that occur more often in those with the disease. GWAS have identified numerous risk genes for neurodegenerative diseases, pointing to biological pathways involved in these conditions.
H
• Hippocampus: A seahorse-shaped brain structure (one in each temporal lobe) crucial for forming new memories and for spatial navigation. The hippocampus is one of the first regions affected in Alzheimer’s disease – early damage here leads to short-term memory loss. It’s also one of the few areas where adult neurogenesis (birth of new neurons) occurs. In a healthy brain, the hippocampus helps convert experiences into long-term memories.
• Huntington’s disease (HD): A hereditary neurodegenerative disorder caused by a mutation in the HTT gene (an expanded CAG repeat) that leads to abnormal huntingtin protein. HD is autosomal dominant – each child of an affected parent has a 50% chance of inheriting it. The disease typically begins in mid-adulthood with involuntary jerking movements (chorea), mood disturbances, and cognitive decline. It relentlessly progresses over 10–20 years. (There is currently no cure; treatments manage symptoms.)
I
• Immunotherapy: Treatments that harness or modulate the immune system to fight disease. In cancer, immunotherapy might make the immune system attack tumours; in neurodegeneration, immunotherapy often refers to antibodies against toxic proteins. For example, monoclonal antibodies like aducanumab or lecanemab target amyloid-beta in Alzheimer’s and help clear it from the brain, effectively recruiting the immune system to remove plaques. Immunotherapy approaches in neurology also include vaccines (e.g. aiming to elicit antibodies against tau or alpha-synuclein) and immune modulators to reduce harmful inflammation in the brain.
• Induced pluripotent stem cells (iPSC): Adult cells (like skin cells) that have been genetically “reprogrammed” back into an embryonic-like pluripotent state. Essentially, scientists introduce a set of factors (Yamanaka factors) that wipe the cell’s identity and make it behave like a stem cell, capable of turning into any cell type. iPSCs allow patient-specific neurons to be grown in a dish for research – for instance, one can take skin cells from a Parkinson’s patient, make iPSC-derived neurons, and study their biology or test drugs on them. In the future, iPSC-derived cells might be used for transplantation therapies.
J
• JNK Pathway (c-Jun N-terminal kinase): A signalling pathway involved in how cells respond to stress, inflammation, and damage. In neurons, overactivation of the JNK pathway can lead to cell death, making it a key player in neurodegeneration. JNK has been linked to the progression of Alzheimer’s, Parkinson’s, and stroke-related brain damage. Inhibiting this pathway is being explored to protect neurons from dying under stress.
• Juvenescence: From Latin juvenis (young), this term refers to the preservation or restoration of youthfulness, especially biological youth. It’s also the name of a biotech company investing heavily in longevity and neurorejuvenation technologies, including senolytics, epigenetic reprogramming, and AI drug discovery. The broader concept of juvenescence captures the goal of not just slowing ageing, but actively reversing it, including in the brain.
• Jitter (Neurophysiology): In brain wave and nerve signal analysis, “jitter” refers to small fluctuations in the timing of neural signals. Increased jitter can signal disordered communication between neurons, often seen in ageing or neurological diseases. In clinical electromyography (EMG), abnormal jitter patterns are diagnostic of neuromuscular diseases.
K
• Ketogenic diet: A diet very high in fats and very low in carbohydrates that forces the body to burn fat for fuel, producing molecules called ketone bodies. Originally developed to treat epilepsy, the keto diet shifts brain metabolism – neurons start using ketones instead of glucose for energy. There is growing interest in ketogenic diets for neurodegenerative diseases: ketones may be a more efficient fuel in ageing brains or might reduce oxidative stress. Some small studies suggest ketogenic diets or ketone supplements could benefit cognitive function, but this is an active area of research and not widely recommended.
L
• Lecanemab: A monoclonal antibody drug designed to bind to and help clear amyloid-beta aggregates from the brain. In clinical trials for early Alzheimer’s, lecanemab (brand name Leqembi) slowed cognitive decline by reducing brain amyloid burden. It was approved as one of the first disease-modifying AD therapies. Treatment requires IV infusions and can have risks like brain swelling or microbleeds, but it represents a new approach targeting the underlying pathology of Alzheimer’s rather than just symptoms.
• Levodopa (L-DOPA): The most effective medication for Parkinson’s disease. Levodopa is a precursor to dopamine that can cross the blood–brain barrier. Once in the brain, it is converted into dopamine, helping replace the dopamine that’s lacking in PD. Given with carbidopa (which prevents its breakdown before reaching the brain), levodopa markedly improves motor symptoms like slowness and rigidity. However, long-term use can lead to fluctuations and dyskinesias (involuntary movements).
• Lewy body: An abnormal intracellular inclusion consisting largely of aggregated alpha-synuclein protein. Lewy bodies are the pathological hallmark of Parkinson’s disease and Lewy body dementia – essentially, they are “blobs” of misfolded protein inside neurons. Their presence is linked to cell dysfunction and death. (Under a microscope, Lewy bodies look like round eosinophilic inclusions in affected neurons.)
• Lewy body dementia (LBD): The second most common form of dementia after AD, associated with Lewy body pathology in the brain. LBD can refer to dementia with Lewy bodies (cognitive symptoms begin before or around the same time as parkinsonian motor symptoms) or Parkinson’s disease dementia (dementia that develops in the context of established Parkinson’s). Common features include fluctuating cognition/alertness, detailed visual hallucinations, parkinsonian movement symptoms, and sensitivity to antipsychotic medications. LBD is often underdiagnosed, but it accounts for an estimated 10–15% of dementias.
• Long-term potentiation (LTP): A long-lasting increase in synaptic strength that occurs when two neurons have been active together repeatedly. LTP is widely considered a cellular mechanism of learning and memory (“neurons that fire together, wire together”). It is typically studied in the hippocampus: after a burst of activity, synapses become more efficient at transmitting signals, an effect that can persist for minutes to hours or longer. Impairment of LTP is observed in models of Alzheimer’s and other conditions that affect memory.
M
• Magnetic Resonance Imaging (MRI): A non-invasive scanning technique that uses strong magnetic fields and radio waves to produce detailed images of the body’s internal structures. MRI is excellent for visualising brain anatomy – it can show brain atrophy (shrinkage) in Alzheimer’s, white matter lesions in vascular dementia, demyelination in multiple sclerosis, etc. Advanced MRI variants include fMRI (for function), DTI (diffusion tensor imaging, for white matter tracts), and MRS (magnetic resonance spectroscopy, for brain chemistry).
• Memantine: A medication used for moderate-to-severe Alzheimer’s disease that regulates glutamate activity. Memantine is an NMDA receptor antagonist – it binds to NMDA glutamate receptors and prevents excessive activation. This is thought to protect neurons from excitotoxicity while still allowing normal glutamate signalling. Clinically, memantine provides modest benefits in cognition and daily function and is often given in combination with a cholinesterase inhibitor.
• Metabolomics: The comprehensive study of metabolites (small molecules like sugars, amino acids, fatty acids) within cells or biological fluids. Metabolomics profiles the chemical fingerprints of cellular processes . In brain aging and disease, metabolomic analyses can reveal disruptions in metabolism – for instance, changes in energy metabolites in Parkinson’s or altered neurotransmitter byproducts in Alzheimer’s. It complements genomics and proteomics by showing the end-products of cellular activity.
• Microglia: The resident immune cells of the brain and spinal cord. Microglia constantly patrol the CNS, ready to engulf (phagocytose) debris, infectious agents, or dead neurons. In a healthy state they help prune synapses during development and support homeostasis. In disease or injury, microglia become activated, which can be double-edged. Activated microglia can clear harmful debris (like amyloid plaques), but overactivation leads to chronic inflammation that can damage neurons. Controlling microglial activation is a therapeutic target in many neurodegenerative diseases.
• Mild Cognitive Impairment (MCI): An intermediate stage between the expected cognitive decline of normal ageing and the more serious decline of dementia. A person with MCI has measurable memory or thinking deficits greater than age peers, but these deficits are not severe enough to significantly interfere with daily life. About 10–15% of people with MCI progress to Alzheimer’s or another dementia each year. However, some remain stable or even revert to normal cognition, especially if underlying causes (sleep apnea, medications, depression, etc.) are addressed.
• Mitochondrial dysfunction: Impaired function of mitochondria—the energy powerhouses of cells—leads to less ATP production and often more reactive oxygen species (free radicals). Neurons are highly dependent on healthy mitochondria for energy. Mitochondrial dysfunction is a common feature of ageing and is implicated in Parkinson’s disease (where certain mitochondrial enzymes are defective) and other neurodegenerative disorders. It contributes to energy failure and oxidative stress in neurons. Compounds like coenzyme Q10 and idebenone have been studied to support mitochondrial function in these diseases.
• Monoclonal antibody: A laboratory-produced antibody engineered to bind to a specific target molecule (antigen) . Monoclonal antibodies (mAbs) are typically proteins (immunoglobulins) designed to mimic the immune system’s ability to recognise pathogens or abnormal cells. In neurodegeneration, mAbs have been developed to target toxic proteins: e.g., antibodies against amyloid-beta (like lecanemab) or tau are in trials for Alzheimer’s. Monoclonal antibodies are usually given by injection or infusion (they cannot be taken as pills due to being proteins).
• mTOR (mechanistic Target of Rapamycin): A central cellular pathway (and protein kinase) that regulates growth and metabolism in response to nutrient and growth factor signals. When mTOR is active, cells grow and build up proteins; when mTOR is inhibited (for example, by the drug rapamycin or during fasting), cells switch to maintenance mode – enhancing cleanup processes like autophagy. Overactive mTOR signalling has been linked to accelerated ageing and reduced autophagy. Rapamycin and similar compounds, by inhibiting mTOR, show lifespan extension in animal models and are being explored for their neuroprotective effects (e.g., promoting clearance of protein aggregates via autophagy).
• Multiple sclerosis (MS): An autoimmune disease in which the immune system attacks the myelin sheath of CNS nerve fibres, leading to demyelination and scarring (sclerosis) in the brain and spinal cord. Depending on where demyelination occurs, MS symptoms can include visual disturbances, limb weakness, numbness, imbalance, and cognitive changes. MS often follows a relapsing-remitting course, especially early on, where acute episodes are followed by partial recovery. It is not primarily a neurodegenerative disease in the sense of Alzheimer’s or Parkinson’s, but over time, MS can cause progressive neurodegeneration due to cumulative damage to axons after myelin is lost.
N
• Neurodegeneration: The progressive loss of structure or function of neurons, including their eventual death. Neurodegenerative processes occur in disorders like Alzheimer’s, Parkinson’s, ALS, and Huntington’s, typically over years or decades. They often involve abnormal protein accumulations, mitochondrial dysfunction, oxidative stress, and other cellular problems that ultimately cause neurons to cease functioning. Neurodegenerative diseases are usually chronic and incurable, which is why research focuses on early detection, slowing progression, or restoring lost function (neurorejuvenation).
• Neurofibrillary tangles (NFTs): Twisted fibres inside neurons composed of an abnormal, aggregated form of tau protein. In healthy neurons, tau helps stabilise microtubules; but in Alzheimer’s and certain other dementias, tau protein becomes hyperphosphorylated and forms insoluble tangles within the neuron. These tangles disrupt the cell’s internal transport system and are toxic to neurons. Along with amyloid plaques, NFTs are a defining pathological feature of Alzheimer’s disease.
• Neurofilament light chain (NfL): A protein that is part of the internal skeleton of neurons (neurofilaments provide structural support to axons). When neurons or axons are damaged, fragments of neurofilament light are released into cerebrospinal fluid and blood. Thus, NfL has emerged as a sensitive biomarker of neurodegeneration and axonal injury – levels are often elevated in Alzheimer’s, Parkinson’s, ALS, MS, and even brain injury. A simple blood test for NfL is being used in research and beginning to enter clinical use to indicate ongoing nerve cell damage.
• Neurogenesis: The process by which new neurons are formed in the brain. Neurogenesis is most active during prenatal development but continues in a few brain regions throughout adulthood (notably the hippocampus and the olfactory bulb). Adult hippocampal neurogenesis is thought to contribute to learning and mood regulation. There is interest in boosting neurogenesis as a therapeutic strategy – for example, exercise and certain antidepressants stimulate neurogenesis, and some hope that this could support brain repair or resilience in ageing and depression.
• Neuroinflammation: Inflammation of the nervous system – an immune response within the brain or spinal cord, often involving activation of microglia and astrocytes. Neuroinflammation can be triggered by infections, trauma, or accumulated proteins. In neurodegenerative diseases, chronic neuroinflammation is common: for instance, microglia around amyloid plaques become activated and release inflammatory cytokines. In moderation, this may help clear debris, but excessive inflammation can further damage neurons. Many experimental therapies aim to modulate neuroinflammation (either damping it down if it’s causing harm, or boosting certain immune functions to clear pathologies).
• Neuroplasticity: The brain’s ability to change and adapt by forming new connections or strengthening/weakening existing ones. Neuroplasticity underlies learning (the brain rewiring itself based on experience) and also allows recovery after injuries (other circuits can sometimes take over lost functions). Even in older adults, the brain retains plasticity, though it may be reduced compared to childhood. Therapies, ranging from cognitive training to brain stimulation devices, often aim to harness neuroplasticity to improve cognitive or motor function.
• Neuroregeneration: The regrowth or repair of nervous tissue, cells or cell products. In the peripheral nervous system, nerves can regenerate after injury (e.g., a cut nerve in your finger can grow back slowly). In the central nervous system, true regeneration is very limited – injured brain or spinal cord neurons generally do not regrow to reconnect in a meaningful way, partly due to inhibitory factors. Neuroregeneration research seeks to overcome this, via methods like stem cell transplants, growth factor delivery, or bioengineered scaffolds, with the hope of restoring lost brain functions.
• Neurorejuvenation: A nascent concept referring to interventions that restore a youthful state or function to ageing neural cells and systems. This could include removing accumulated cellular damage, resetting epigenetic ageing markers (as in partial cellular reprogramming), clearing senescent cells (senolytics), or using young systemic factors (like young blood or plasma) to revitalise an old brain. The goal of neurorejuvenation is to reverse or slow brain ageing and repair early neurodegenerative changes, essentially “making old neurons young again.” (This is an active area of research, inspired by findings such as heterochronic parabiosis experiments.)
• Neurotransmitter: A chemical messenger that transmits a signal from one neuron to another across a synapse. When an electrical impulse reaches a synapse, it triggers release of neurotransmitter molecules (e.g. glutamate, GABA, dopamine, serotonin, acetylcholine) from the presynaptic neuron. These molecules diffuse across the synaptic cleft and bind receptors on the postsynaptic cell, influencing its activity. Neurotransmitters underlie all brain communication – for instance, memory loss in Alzheimer’s is linked to deficits in acetylcholine, and movement symptoms in Parkinson’s are due to lack of dopamine.
• Neurotrophic factors: Proteins that support the growth, survival, and differentiation of neurons. They are essentially nurturing molecules that help neurons thrive. Examples include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and others. In neurodegenerative disease research, providing neurotrophic factors or boosting their signalling is a strategy to try to rescue dying neurons or encourage regeneration (e.g., trials delivering GDNF in Parkinson’s, or BDNF mimetics in ALS).
O
• Oligodendrocyte: A type of glial cell in the CNS that produces myelin, the fatty sheath that wraps around axons to insulate them and speed up nerve impulses . Each oligodendrocyte can myelinate multiple axon segments (like an octopus wrapping tentacles around different wires). In multiple sclerosis, oligodendrocytes are damaged by the immune system, leading to demyelination. Loss of oligodendrocytes and myelin can also occur in normal ageing and contribute to cognitive slowing (since signals travel less efficiently without full myelin).
• Organoid (brain organoid): A three-dimensional mini-organ grown from stem cells in vitro, replicating some structural and functional aspects of a real brain. Brain organoids (sometimes called “mini-brains”) are tiny balls of neural tissue – a few millimetres wide – containing neurons and supporting cells that self-organise into layers and regions reminiscent of a developing brain. They are used to study brain development, model diseases (e.g., organoids with Alzheimer’s mutations develop plaques and tangles), and test drugs in a human-relevant system without needing an actual patient.
• Oxidative stress: An imbalance between the production of reactive oxygen species (free radicals) and the body’s antioxidant defences. Excess reactive oxygen can damage cellular components (DNA, proteins, lipids) through oxidation. The brain is especially vulnerable to oxidative stress because of its high oxygen use and fatty tissue. Oxidative stress is implicated in ageing and virtually all neurodegenerative diseases – for example, damaged molecules from oxidative stress are found in Alzheimer’s and Parkinson’s brains. Antioxidants (like vitamin E or compounds like coenzyme Q10) have been studied as therapies, though with limited success so far.
P
• Parabiosis: An experimental technique in which two living animals are surgically joined to share a circulatory system. In aging research, heterochronic parabiosis (joining a young and an old mouse) has yielded fascinating results: the old mouse often shows rejuvenated tissues (better muscle repair, improved memory, etc.) presumably due to beneficial factors in the young blood, whereas the young mouse can show signs of premature aging due to factors in old blood. These experiments suggest blood-borne molecules play a role in ageing, spurring interest in identifying pro-youth factors (or conversely, ageing “toxins”) in the bloodstream.
• Parkinson’s disease (PD): A neurodegenerative disorder characterised primarily by motor symptoms (tremor, rigidity, bradykinesia, postural instability) due to the loss of dopamine-producing neurons in the substantia nigra region of the brain. Pathologically, it features Lewy bodies (alpha-synuclein protein aggregates) in surviving neurons. Beyond movement issues, Parkinson’s can involve depression, sleep disturbances, autonomic dysfunction, and cognitive decline (especially in late stages). Treatments include dopamine-replacing drugs (like levodopa), deep brain stimulation, and investigational therapies aimed at slowing neuron loss.
• Partial cellular reprogramming: A cutting-edge experimental strategy where the expression of youth-associated genes (the Yamanaka factors: OCT4, SOX2, KLF4, c-MYC) is turned on transiently in an old cell to make it biologically younger without erasing its identity entirely. In mice, cycles of partial reprogramming have been shown to reverse some markers of ageing and improve tissue function (for example, improving vision in old mice by rejuvenating retinal cells). The idea is to reset epigenetic ageing clocks and restore a youthful gene expression profile in cells without fully converting them to stem cells. This approach is very experimental but represents a potential future form of “rejuvenation” therapy.
• PET scan (Positron Emission Tomography): A functional imaging technique that uses a radioactive tracer to visualize metabolic or molecular activity in the body . In the brain, PET can measure glucose metabolism (using FDG-PET) to identify hypometabolic areas in dementia, or detect specific proteins with specialised tracers (e.g. amyloid PET and tau PET scans to detect Alzheimer’s pathology in vivo). PET scans are powerful for early diagnosis and research, showing changes in brain function that often precede structural changes visible on MRI.
• Pharmacology: The branch of science (and medicine) that studies drugs and their interactions with living organisms. It includes pharmacodynamics (what drugs do to the body – mechanism of action, effects) and pharmacokinetics (what the body does to drugs – absorption, distribution, metabolism, excretion). In neurodegeneration, pharmacology underpins the development of medications to alleviate symptoms (like dopaminergic drugs for PD, cholinesterase inhibitors for AD) and the search for disease-modifying compounds (like inhibitors of protein aggregation or enhancers of cell survival pathways).
• Prion: A misfolded protein that can transmit its abnormal shape onto normal variants of the same protein, essentially “infecting” them and causing them to misfold as well. Prions are infamous for causing Creutzfeldt-Jakob disease and mad cow disease – unique neurodegenerative diseases that are transmissible by infectious protein (no virus or bacteria involved). In prion diseases, a normal brain protein (PrP) misfolds into a toxic form that aggregates and triggers chain-reaction misfolding of PrP in other cells , leading to rapid neurodegeneration. Interestingly, researchers have noted prion-like spreading of proteins in more common diseases (e.g. misfolded tau or alpha-synuclein spreading through the brain in Alzheimer’s or Parkinson’s), though those conditions are not infectious in the way prion diseases are.
• Proteomics: The large-scale study of all proteins (the proteome) expressed by a cell, tissue, or organism. Proteomic analyses use techniques like mass spectrometry to identify and quantify thousands of proteins at once. In neurodegenerative research, proteomics can reveal which proteins are altered in disease (e.g. decreased synaptic proteins, increased inflammatory proteins) and discover new biomarkers or therapeutic targets. It moves beyond genetics to tell us what is actually happening at the protein level in cells.
• Proteostasis: A portmanteau of “protein homeostasis,” referring to the cell’s maintenance of a balanced and functional protein pool. Proteostasis involves ensuring proteins are properly folded, trafficking them to where they’re needed, and degrading proteins that are damaged or no longer required. The ubiquitin-proteasome system and autophagy are key components of proteostasis. When proteostasis breaks down, misfolded proteins accumulate – a central problem in neurodegenerative diseases. Many cellular stress responses (like the heat shock response and the unfolded protein response) exist to uphold proteostasis, and boosting these responses is being explored as a therapy (for example, enhancing proteasome activity or upregulating chaperone proteins to refold misfolded proteins).
Q
• Quercetin: A plant-derived flavonoid found in foods like onions, apples, and berries. It has antioxidant, anti-inflammatory, and senolytic properties, which can help remove senescent “zombie” cells. Combined with dasatinib, it’s being tested as a therapy to rejuvenate tissues and delay ageing, including in the brain. Animal studies suggest it may improve memory and reduce inflammation in neurodegenerative conditions.
• Quantified Self (QS): A movement that uses technology to track personal health data, like sleep, cognition, mood, and biomarkers, to optimise well-being. In the context of neurodegeneration, QS tools (wearables, apps, home cognitive tests) can provide early warning signs of decline or help assess the impact of lifestyle changes or supplements on brain health.
• QSM (Quantitative Susceptibility Mapping): An advanced MRI technique that maps the magnetic properties of tissues, especially iron content in the brain. Iron accumulation in specific regions (e.g., substantia nigra in Parkinson’s) is a hallmark of several neurodegenerative diseases. QSM allows researchers to measure these deposits non-invasively and may aid in early diagnosis or tracking disease progression.
R
• Rapamycin: A drug (originally found in soil from Easter Island) that inhibits the mTOR pathway and has immunosuppressant properties. Rapamycin is used to prevent organ transplant rejection, but in lower doses it has attracted attention as a geroprotective agent – it extended lifespan in many species from yeast to mice by mimicking a calorie-restricted metabolic state. In the context of neuroaging, rapamycin’s inhibition of mTOR promotes autophagy (helping cells clear out garbage) and may protect neurons from age-related degeneration. Clinical trials are underway to see if rapamycin or similar drugs can improve age-related cognitive function or slow neurodegenerative disease progression.
• Reactive oxygen species (ROS): Highly reactive oxygen-containing molecules (such as superoxide, hydroxyl radical, and hydrogen peroxide) that are natural byproducts of metabolism. At controlled levels, ROS play roles in cell signalling. But excess ROS causes oxidative damage to DNA, proteins, and lipids. Antioxidant systems (like glutathione, catalase, superoxide dismutase) usually neutralise ROS. When ROS production outstrips defences, oxidative stress results, contributing to cell injury in ageing and diseases. Neurons produce ROS, especially in mitochondria; if mitochondria become dysfunctional, ROS can spike and drive neurodegeneration.
• Regenerative medicine: A field of medicine aiming to repair or replace damaged cells, tissues, or organs to restore normal function . It encompasses stem cell therapy, tissue engineering, and stimulating endogenous repair processes. In neurology, regenerative medicine approaches include transplanting stem-cell-derived neurons to replace those lost (e.g. dopaminergic neurons in Parkinson’s), using bioengineered scaffolds or growth factors to encourage axon regrowth after spinal cord injury, or gene editing to correct mutations in neural cells. It’s an ambitious area that intersects with bioengineering and advanced therapeutics.
S
• Senescence (cellular): A state in which a cell permanently stops dividing (a cell-cycle arrest) but remains metabolically active. Senescent cells often secrete pro-inflammatory factors (the SASP, senescence-associated secretory phenotype) that can harm neighbouring cells. Cellular senescence is a double-edged sword – it helps prevent cancer by halting the growth of damaged cells, and aids in wound healing. Still, the accumulation of senescent cells over time is thought to contribute to tissue ageing and chronic inflammation. In the ageing brain, senescent glial cells may create a toxic milieu. Clearing senescent cells with senolytic drugs is a strategy being investigated to combat ageing and neurodegenerative disease.
• Senolytics: Drugs (or other interventions) that selectively induce death of senescent cells, thereby purging them from tissues. By removing senescent cells, senolytics aim to reduce the inflammatory, tissue-degrading environment these “zombie” cells create, potentially improving organ function in ageing or disease. Examples of senolytics under study include the combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid), which in mice cleared senescent cells and improved aspects of healthspan. In the brain, senolytics might help by eliminating senescent microglia or astrocytes that are contributing to neuroinflammation.
• Small molecule: In pharmacology, an organic compound of low molecular weight (typically <900–1000 daltons) that can easily diffuse into cells and often can be taken orally. Most traditional drugs are small molecules – for example, levodopa, donepezil, and memantine are all small molecules. They contrast with “biologics” like antibodies, which are large and usually injected. Small-molecule drugs in neurodegeneration might aim to inhibit an enzyme (e.g. BACE inhibitors to stop amyloid production) or stabilise a protein’s folding, etc. Their small size often allows them to cross the blood–brain barrier more readily than larger biologics.
• Stem cells: Undifferentiated cells that can divide and give rise to specialised cell types. In the brain, neural stem cells exist in certain regions (like the subventricular zone and hippocampus) and can produce new neurons and glia, albeit in limited numbers. Stem cell therapy for neurodegeneration involves either activating these endogenous stem cells or transplanting external stem cells (e.g. embryonic or induced pluripotent stem cell-derived) to replace lost neurons or modulate the environment. For example, clinical trials have transplanted mesenchymal stem cells or fetal neural cells into the brains of patients with ALS or Parkinson’s, with mixed results so far.
• Synapse: The junction between two neurons (or a neuron and another cell) where communication occurs. In a chemical synapse, an electrical impulse in the presynaptic neuron triggers the release of neurotransmitters that cross the tiny gap and bind to receptors on the postsynaptic neuron. Synapses can strengthen or weaken over time (see LTP and Neuroplasticity). Loss of synapses is an early feature of Alzheimer’s disease, correlating strongly with cognitive decline – often even before massive neuron death occurs, synaptic dysfunction is present.
• Systems biology: An interdisciplinary approach to understanding biology as a complex network of interactions, rather than isolating single components. Systems biology uses computational and mathematical modelling of complex biological systems, integrating data from genomics, proteomics, metabolomics, and cell biology to simulate how cells and organs function as a whole. In neurodegeneration, a systems biology approach might model the network of molecular changes in a neuron during Alzheimer’s to identify key “hub” molecules, or simulate how different cell types (neurons, microglia, astrocytes, blood vessels) interact in the brain’s ecosystem to drive disease.
T
• Tau protein: A protein that stabilises microtubules (structural support rods) in neurons. In disease, tau can undergo abnormal chemical changes (hyperphosphorylation) that cause it to detach from microtubules and aggregate into insoluble filaments. These tau aggregates form the neurofibrillary tangles inside neurons in Alzheimer’s and other tauopathies. Because tau tangles correlate with neuronal death and cognitive decline, therapies are being developed to reduce tau aggregation or spread.
• Tauopathy: A class of neurodegenerative disease characterised by the accumulation of abnormal tau protein in the brain. Alzheimer’s is a primary example (a mixed amyloid/tauopathy), but there are others: frontotemporal lobar degeneration with tau (e.g. Pick’s disease), progressive supranuclear palsy, corticobasal degeneration, and chronic traumatic encephalopathy (CTE) are all tauopathies. Depending on the disease, tau deposits might occur in neurons and/or glial cells, and in different brain regions, leading to different clinical symptoms, but what unites them is that misfolded tau is a central driver of neurodegeneration.
• TDP-43: Short for TAR DNA-binding protein 43, a protein involved in RNA processing. TDP-43 is normally located mostly in the nucleus of cells, but in certain diseases, it mislocalises to the cytoplasm and aggregates. TDP-43 proteinopathies include the majority of ALS (amyotrophic lateral sclerosis) and about half of frontotemporal dementia cases, where TDP-43-positive inclusions are found in degenerating neurons. TDP-43 pathology is thought to disrupt RNA metabolism and contribute to neuron death in these conditions. (Notably, a subset of Alzheimer’s patients also have TDP-43 pathology, termed LATE – limbic-predominant age-related TDP-43 encephalopathy – which can worsen cognitive impairment.)
• Telomeres: Repetitive DNA sequences at the ends of chromosomes that protect them from degradation (often likened to the plastic aglets at shoelace ends). Telomeres shorten slightly each time a cell divides. When they become critically short, the cell may enter senescence or die. Telomere length is considered a marker of cellular ageing – shorter telomeres are associated with age-related diseases. In the brain, most neurons don’t divide, so telomere shortening is more relevant to dividing cells (like glia or peripheral blood cells), but systemic telomere length (e.g., in blood leukocytes) has been studied for correlations with dementia risk, with mixed results.
• Transcranial Magnetic Stimulation (TMS): A non-invasive therapy that uses magnetic fields to stimulate nerve cells in specific brain regions. An electromagnetic coil placed on the scalp delivers magnetic pulses that induce electrical currents in the underlying brain tissue. Repetitive TMS is an FDA-approved treatment for major depression (targeting the prefrontal cortex) and is being explored for OCD, PTSD, and as a tool in stroke rehabilitation. In neuroscience research, TMS can transiently disrupt or excite parts of the brain to study their function (for example, knocking out a region to see if a person fails at a task, indicating that region’s involvement).
• Transcriptomics: The large-scale study of the transcriptome – the complete set of RNA transcripts produced by the genome under specific conditions. This is usually done with technologies like microarrays or RNA sequencing, which can capture the expression levels of thousands of genes at once. Transcriptomics allows scientists to see which genes are active (and how active) in, say, a healthy neuron versus an Alzheimer’s neuron. Such comparisons can point to pathways that are up- or down-regulated in disease (e.g., increased inflammation genes, decreased synaptic genes), providing clues for therapeutic targets.
U
• Ubiquitin–proteasome system (UPS): A major cellular pathway for protein degradation and quality control. Proteins that are misfolded or no longer needed are tagged with a small protein called ubiquitin, marking them for destruction. The tagged proteins are then fed into proteasomes – barrel-shaped protease complexes – which break them down into peptides. The UPS helps prevent the toxic buildup of proteins. Impairment of the UPS can lead to the accumulation of proteins like tau, synuclein, or huntingtin. In fact, many neurodegenerative diseases feature overwhelmed or dysfunctional proteasome activity as aggregated proteins resist degradation.
V
• Vascular dementia: Cognitive impairment and dementia caused by brain damage from impaired blood flow (often strokes or chronic small vessel disease). It is the second most common type of dementia after Alzheimer’s. Symptoms can include slowed thinking, difficulty with organisation, focus and problem-solving, mood changes, and memory loss (though memory is often less affected than in Alzheimer’s until later). The course can be stepwise (worsening after each stroke) or gradual if due to small vessel changes. Managing cardiovascular risk factors is key in prevention and treatment.
• Viral vector: A virus that has been modified to deliver therapeutic genes into cells. By stripping out a virus’s disease-causing genes and inserting a gene of interest, researchers create a delivery tool that uses the virus’s natural ability to infect cells. Common viral vectors include AAV (adeno-associated virus), adenovirus, and lentivirus. In gene therapy trials for neurologic disorders, viral vectors have been used to shuttle genes into the brain, for example, giving neurons the gene for GDNF (a growth factor) or a corrective gene for a metabolic enzyme. One challenge is targeting vectors to the right cells and avoiding immune responses.
W
• Wearables: Wearable devices (like smartwatches, fitness bands, or other sensor-equipped gadgets) that track health metrics continuously. In brain ageing and neurodegeneration, wearables can monitor movement, sleep patterns, heart rate and other physiological signals over long periods. This data helps detect subtle changes – for example, gait slowing or altered sleep – that might be early signs of cognitive decline or neurological disease. Wearables thus serve as digital biomarkers, enabling early intervention and personalized monitoring of brain health outside the clinic.
• Whole-brain imaging: Techniques allowing researchers and clinicians to visualise the entire brain’s structure or activity simultaneously. This can include advanced neuroimaging scans in living people, such as whole-brain MRI or PET scans, which show anatomy or metabolic activity across the entire brain. It also includes experimental methods like clearing and light-sheet microscopy in lab models, which can render an entire mouse brain transparent and then image it in 3D at cellular resolution. Whole-brain imaging is valuable for mapping neural connections, observing how neurodegenerative pathology (like protein plaques or cell loss) spreads through the brain, and assessing the global effects of therapies. By capturing the “big picture” of the brain, these methods help understand brain-wide network changes in ageing or disease.
• Wnt signalling: A cell communication pathway crucial for development, cell growth, and tissue maintenance. Wnt proteins bind to cell surface receptors and trigger signals influencing gene expression in cell survival, growth, and differentiation. In the brain, Wnt signalling helps guide embryonic neural development and supports adult brain functions like neurogenesis (creating new neurons) and synaptic plasticity. Dysregulation of Wnt signalling has been linked to neurodegenerative diseases – for example, defective Wnt pathway activity is associated with conditions like Alzheimer’s and Parkinson’s. Researchers are exploring therapies that carefully boost Wnt signalling in the aged brain, hoping to promote neuron survival and even regeneration. However, because overactive Wnt pathways can cause cancer, any such treatments aim to restore normal Wnt levels without overstimulation.
X
• X-chromosome inactivation: A genetic regulatory process in female mammals where one of the two X chromosomes in each cell is mostly “turned off.” This inactivation happens early in development and is random in each cell, creating a mosaic where roughly half the cells use one X chromosome and the other half use the alternate X. In the context of neurodegeneration, X-chromosome inactivation can influence how X-linked genes (those on the X chromosome) impact brain health. For instance, if a female carries a mutation for an X-linked neurodegenerative or neurodevelopmental disorder, some of her cells may inactivate the X with the mutation, potentially reducing the disease’s severity. Patterns of X-inactivation skewing (where one X is preferentially active in more cells) have been studied as a factor in sex differences seen in certain brain diseases . Understanding X-chromosome inactivation helps explain why some X-linked conditions (like certain types of intellectual disability or rare neurogenetic disorders) might present differently in women versus men, and it sheds light on the complex genetic landscape of neurodegenerative risk.
• Xenografts: Transplanting living cells or tissues from one species into another (the prefix xeno- means “foreign”). In neurodegeneration research, xenograft models are used to study human brain cells in a live organism or to test regenerative therapies. For example, scientists can graft human neural stem cells or brain organoids into the brain of a mouse. The mouse then carries human neurons or glial cells, allowing researchers to observe human-specific aspects of neuron development, protein aggregation, or cell interactions in a controlled setting . Such chimeric models (mixing species) are especially useful for studying diseases like Alzheimer’s or Parkinson’s: human cells can develop pathological changes (plaques, tangles, etc.) in a living brain environment, or researchers can see if the grafted cells help repair damage. Xenografts are also being explored experimentally as therapies – for instance, transplanting pig or fetal cells into patients with Parkinson’s disease – though immune rejection and ethical considerations are challenges. Overall, xenograft techniques are a powerful experimental approach to bridge the gap between petri-dish studies and human clinical reality in neurodegeneration research.
Y
• Yamanaka factors: A set of four specific genes (Oct4, Sox2, Klf4, and c-Myc) that can reprogram adult cells back to a youthful, stem-cell-like state. Discovered by Dr. Shinya Yamanaka, these factors earned him a Nobel Prize in 2012 for enabling the creation of induced pluripotent stem cells. In the context of brain aging and neurorejuvenation, the controlled use of Yamanaka factors is being explored to reverse cellular aging without fully resetting cell identity. Experiments in mice have shown that partial reprogramming (turning on the Yamanaka factors for a short duration) can rejuvenate cells. For example, applying Yamanaka factors in old mice has been reported to restore vision by making aging eye neurons function more youthfully, and recent research indicates that neurons can be made “younger” and more resilient to neurodegenerative disease with this approach . The key is inducing a partial rewind of the epigenetic clock of cells – enough to revive their youthful gene activity and repair mechanisms, but not so much that cells lose their specialized functions or start dividing uncontrollably. Yamanaka factors represent a cutting-edge strategy to turn back the clock on cells, offering hope that one day we might rejuvenate aging brain tissue and treat diseases like Alzheimer’s at their root cause.
• Young plasma: This refers to blood plasma taken from a young individual, which has become a hot topic due to its potential rejuvenating effects on older organisms. Groundbreaking experiments in mice showed that joining the circulatory systems of a young and an old mouse (a procedure called heterochronic parabiosis) led to the old mouse experiencing benefits to its brain and other organs. Similarly, giving old mice injections of young blood plasma improved their memory and learning capabilities . For instance, old mice that received young plasma performed better on maze tests than those given plasma from old mice, and their brains showed signs of increased synaptic plasticity and even new neuron growth . The young plasma is thought to contain “youth factors” – beneficial proteins, hormones, or microRNAs that enhance tissue repair and reduce inflammation. In contrast, old blood has factors that may impair cell function. Researchers (in labs led by people like Tony Wyss-Coray at Stanford) are working to identify which factors in young blood are responsible for these effects. The ultimate goal is to develop therapies for humans that mimic young blood’s benefits – potentially treatments to boost brain repair, improve memory, and fend off neurodegenerative changes as we age, without needing actual blood transfusions.
Z
• Zebrafish models: Zebrafish are small freshwater fish that have emerged as an important model organism in neuroscience and aging research. Despite their simplicity, zebrafish share a similar basic brain structure with mammals and have many of the same types of neurons and neurotransmitters. Uniquely, zebrafish have remarkable regenerative abilities – they can regrow parts of their brain and spinal cord after injury. They also continually produce new neurons throughout life , which helps them resist neurodegenerative changes that would permanently debilitate mammals. Researchers take advantage of zebrafish for several reasons: (1) Young zebrafish are transparent, so scientists can directly watch neurons and blood vessels in a living brain under a microscope. (2) Zebrafish breed rapidly and develop quickly, making genetic studies and drug screening efficient. (3) It’s relatively easy to create zebrafish models of human brain diseases by genetic manipulation (for example, inserting human genes associated with Alzheimer’s or Parkinson’s). As a result, zebrafish have been used to study the processes of neurodegeneration in vivo and to test potential drugs that might prevent neuron loss or enhance regeneration. Their ability to repair their brains naturally provides clues for human neurorejuvenation research – if we understand how zebrafish regrow neurons, we might learn how to stimulate similar repair in the human brain .
• Zinc homeostasis in neurons: The maintenance of proper zinc levels in brain cells. Zinc is an essential trace metal that plays several roles in the nervous system. A portion of zinc in the brain resides in synaptic vesicles of neurons (especially in regions like the hippocampus) and is released during neural activity, where it can modulate neurotransmitter receptors and influence memory formation. Neurons must keep zinc in a delicate balance – too little zinc impairs brain function, whereas too much zinc can become toxic . For example, in normal conditions zinc released at synapses helps with signaling, but during events like stroke or traumatic brain injury, an excessive surge of zinc into neurons can trigger cell death . Conversely, chronic zinc deficiency may reduce neurogenesis (growth of new neurons) and contribute to cognitive decline . The brain has dedicated proteins (zinc transporters and binding proteins) that tightly regulate zinc levels in cells. In neurodegenerative diseases such as Alzheimer’s, this zinc balance can be disrupted – zinc can abnormally accumulate around amyloid plaques, and some research suggests that mismanagement of zinc inside neurons might promote clumping of proteins or oxidative stress. Therefore, “zinc homeostasis” refers to all the processes that keep zinc levels optimal in neurons. Therapies that restore proper zinc levels (either by supplementing zinc, chelating excess zinc, or modulating transporter proteins) are being investigated as they could protect neurons and possibly slow down degenerative processes.
• “Zombie” cells (senescent cells): A colloquial term for senescent cells – cells that have irreversibly stopped dividing but refuse to die. As organisms age, various cells (including brain cells like certain glia, and possibly some neurons) enter this senescent state. They are often called “zombie” cells because they are metabolically active but no longer function like normal healthy cells, and they can wreak havoc by releasing a “toxic cocktail” of inflammatory and tissue-degrading molecules . This secretion, known as the SASP (senescence-associated secretory phenotype), can damage neighboring healthy cells and is thought to contribute to aging and degeneration in tissues, including the brain . In the brain, senescent cells have been implicated in conditions like Alzheimer’s disease – for instance, senescent microglia or astrocytes (types of brain support cells) might drive inflammation and neuronal death. Clearing these zombie cells has shown promise in animal studies: when mice were treated with senolytics (drugs that remove senescent cells), their cognitive function improved and pathology reduced in models of neurodegenerative disease . This has led to early clinical trials testing senolytic drugs in people at risk for Alzheimer’s . In summary, “zombie cells” are a hallmark of aging that represent a new target for neurorejuvenation – by finding ways to eliminate or rejuvenate these senescent cells, scientists hope to prevent them from promoting brain aging and dysfunction.